As our understanding of the metabolic–psychiatric interface deepens, GLP-1 RAs may come to represent a paradigm shift in the management of mood disorders, one that moves beyond symptomatic control to address the systemic basis of treatment resistance. This evidence concerns the gene GCG and mood disorder.